Evosep develops new solutions to make clinical proteomics 100 times more robust and 10 times faster.
Evosep has raised $40.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2023.
Evosep's investors include Novo Holdings, Vaekstfonden.
Evosep is headquartered in Odense, Denmark.
Evosep develops new solutions to make clinical proteomics 100 times more robust and 10 times faster.
Evosep is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Evosep — Funding & Investors." VCBacked, January 9, 2023, https://www.vcbacked.co/company/evosep. Accessed September 30, 2026.
VCBacked. (2023). Evosep — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/evosep
{{cite web |title=Evosep — Funding & Investors |url=https://www.vcbacked.co/company/evosep |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated